Daiichi Nets Novel HER-3 Antibody With U3 Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
German firm partners with Amgen on the IND-ready mAb.
You may also be interested in...
Daiichi Sankyo Ranbaxy Acquisition Very Much Alive
Details of tender offer at 40 percent premium revealed.
Daiichi Sankyo Ranbaxy Acquisition Very Much Alive
Details of tender offer at 40 percent premium revealed.
Daiichi Sankyo Expands European Sales Presence By Hiring 130 Merck KGaA Reps
Goal is a 70/30 split of ROW and Japanese revenues, firm says.